Cargando…
Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis
The interaction between intestinal microecological dysregulation, altered inflammatory factors, and cirrhosis is unclear. The aim of this systematic review and meta-analysis was to synthesize the results of previous studies to assess the efficacy of probiotics in the treatment of cirrhosis and their...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590617/ https://www.ncbi.nlm.nih.gov/pubmed/37872967 http://dx.doi.org/10.1515/biol-2022-0741 |
_version_ | 1785124027672559616 |
---|---|
author | Xia, Qinglan Lei, Yumeng Wang, Jiadun Wang, Qiang |
author_facet | Xia, Qinglan Lei, Yumeng Wang, Jiadun Wang, Qiang |
author_sort | Xia, Qinglan |
collection | PubMed |
description | The interaction between intestinal microecological dysregulation, altered inflammatory factors, and cirrhosis is unclear. The aim of this systematic review and meta-analysis was to synthesize the results of previous studies to assess the efficacy of probiotics in the treatment of cirrhosis and their effect on inflammatory factors, as well as to explore the relationship between gut microecological dysregulation and liver disease to gain a deeper understanding of this interaction. Up to December 2022, eligible studies were identified by searching the following databases: National Knowledge Infrastructure (CNKI), Wanfang Data, Web of Science, PubMed, Embase, Medline, and the Cochrane Library. Statistical analysis was performed using software RevMan Version 5.4. A total of 33 eligible randomized controlled trials were included in the study, and data on probiotic strains, duration of intervention, measures in the control group, and outcomes were extracted and evaluated. Compared to the control group, the experimental group had significant improvements in overall efficacy. The results of the meta-analysis revealed that probiotic use significantly decreased biochemical parameters for liver function, including aspartate transaminase, alanine aminotransferase, and total bilirubin. Similar result was obtained in interleukin-6, tumor necrosis factor-α, and endotoxin. However, probiotic intervention did not significantly affect interleukin-2 and interleukin-10. The current meta-analysis illustrates that probiotic supplementation reduces inflammatory markers and biochemical parameters for liver function in patients with cirrhosis, suggesting that probiotic management may be a novel treatment for cirrhosis. Furthermore, the interaction of the gut microbiota, associated metabolites, and inflammation factors with cirrhosis may provide a promising therapeutic target for the pharmacological and clinical treatment of cirrhosis. |
format | Online Article Text |
id | pubmed-10590617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | De Gruyter |
record_format | MEDLINE/PubMed |
spelling | pubmed-105906172023-10-23 Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis Xia, Qinglan Lei, Yumeng Wang, Jiadun Wang, Qiang Open Life Sci Review Article The interaction between intestinal microecological dysregulation, altered inflammatory factors, and cirrhosis is unclear. The aim of this systematic review and meta-analysis was to synthesize the results of previous studies to assess the efficacy of probiotics in the treatment of cirrhosis and their effect on inflammatory factors, as well as to explore the relationship between gut microecological dysregulation and liver disease to gain a deeper understanding of this interaction. Up to December 2022, eligible studies were identified by searching the following databases: National Knowledge Infrastructure (CNKI), Wanfang Data, Web of Science, PubMed, Embase, Medline, and the Cochrane Library. Statistical analysis was performed using software RevMan Version 5.4. A total of 33 eligible randomized controlled trials were included in the study, and data on probiotic strains, duration of intervention, measures in the control group, and outcomes were extracted and evaluated. Compared to the control group, the experimental group had significant improvements in overall efficacy. The results of the meta-analysis revealed that probiotic use significantly decreased biochemical parameters for liver function, including aspartate transaminase, alanine aminotransferase, and total bilirubin. Similar result was obtained in interleukin-6, tumor necrosis factor-α, and endotoxin. However, probiotic intervention did not significantly affect interleukin-2 and interleukin-10. The current meta-analysis illustrates that probiotic supplementation reduces inflammatory markers and biochemical parameters for liver function in patients with cirrhosis, suggesting that probiotic management may be a novel treatment for cirrhosis. Furthermore, the interaction of the gut microbiota, associated metabolites, and inflammation factors with cirrhosis may provide a promising therapeutic target for the pharmacological and clinical treatment of cirrhosis. De Gruyter 2023-10-17 /pmc/articles/PMC10590617/ /pubmed/37872967 http://dx.doi.org/10.1515/biol-2022-0741 Text en © 2023 the author(s), published by De Gruyter https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. |
spellingShingle | Review Article Xia, Qinglan Lei, Yumeng Wang, Jiadun Wang, Qiang Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis |
title | Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis |
title_full | Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis |
title_fullStr | Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis |
title_full_unstemmed | Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis |
title_short | Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis |
title_sort | probiotic management and inflammatory factors as a novel treatment in cirrhosis: a systematic review and meta-analysis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590617/ https://www.ncbi.nlm.nih.gov/pubmed/37872967 http://dx.doi.org/10.1515/biol-2022-0741 |
work_keys_str_mv | AT xiaqinglan probioticmanagementandinflammatoryfactorsasanoveltreatmentincirrhosisasystematicreviewandmetaanalysis AT leiyumeng probioticmanagementandinflammatoryfactorsasanoveltreatmentincirrhosisasystematicreviewandmetaanalysis AT wangjiadun probioticmanagementandinflammatoryfactorsasanoveltreatmentincirrhosisasystematicreviewandmetaanalysis AT wangqiang probioticmanagementandinflammatoryfactorsasanoveltreatmentincirrhosisasystematicreviewandmetaanalysis |